Phoenix Pharmalabs, Inc. is a pre-clinical pharmaceutical company based in Woods Cross, UT, dedicated to developing potent and safe pain therapies without the risk of addiction and serious side effects. Their lead candidate, PPL-138, offers robust preclinical validation of potent pain relief with 100X potency of morphine and a low risk of abuse and addiction. Additionally, their second drug candidate, PPL-103, shows promising potential for the treatment of addiction and pain, with reduced opioid side effects.
With a mission to address the immense unmet medical need for comprehensive solutions to opioid abuse, addiction, and mortality, Phoenix Pharmalabs aims to bring their unique opioid receptor characteristics to the market. Their portfolio of drugs under development aims to provide effective treatment for moderate to severe acute and chronic pain without the dangerous side effects associated with other opioids. Through strategic partnerships and ongoing clinical trials, Phoenix Pharmalabs is committed to revolutionizing pain therapy and improving the lives of millions affected by opioid-related issues.
Generated from the website